During disease progression from primary towards metastatic prostate cancer (PCa), and in
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …

Simple Summary The incidence of prostate cancer is rising, primarily due to its prevalence
among elderly men, and with increased life expectancy, these numbers are expected to …

Bone metastasis is a frequent and incurable consequence of advanced prostate cancer
(PC). An interplay between disseminated tumor cells and heterogeneous bone resident cells …

How prostate cancer cells and their precursors mediate changes in the tumor
microenvironment (TME) to drive prostate cancer progression is unclear, in part due to the …

Glutamine metabolism in tumor microenvironments critically regulates antitumor immunity.
Using the glutamine-antagonist prodrug JHU083, we report potent tumor growth inhibition in …

Abstract Background The quinoline‐3‐carboxamide, Tasquinimod (TasQ), is orally active as
a maintenance therapy with an on‐target mechanism‐of‐action via allosteric binding to …

Prostate cancer (PC) is the third most frequently diagnosed cancer worldwide and the
second most frequent in men. Several risk factors can contribute to the development of PC …

Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation
for metastatic prostate cancer and encompasses a heterogeneous patient population with …

Mounting evidence suggests that the immune landscape within prostate tumors influences
progression, metastasis, treatment response, and patient outcomes. In this study, we …

Adoptive transfer of immature myeloid cells lacking the repressive NF-κB p50 subunit (p50-
IMC) slows the growth of syngeneic murine prostate cancer and other tumors. Directing p50 …